Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Giovanni F M Strippoli

Showing results (1-10 of 218) with videos related to

Pageof 22
Sort By:
Trials|June 11, 2010
Effects of the dose of erythropoiesis stimulating agents on cardiovascular events, quality of life, and health-related costs in hemodialysis patients: the clinical evaluation of the dose of erythropoietins (C.E. DOSE) trial protocolGiovanni F M Strippoli,
Ethnicity & Disease|June 2, 2009
Risk factors for the development and progression of renal diseases in disadvantaged populations: role of the renin-angiotensin system blockadeAusilia Maione, Giovanni F M Strippoli
Journal of Nephrology|November 8, 2011
Should we shift toward higher blood pressure targets in patients with chronic kidney disease?Giorgio Gentile, Giovanni F M Strippoli
Pediatric Nephrology (Berlin, Germany)|February 25, 2026
Artificial intelligence in pediatric nephrology: current applications and emerging frameworks for evidence generationGiovanni Pellegrino, Giovanni F M Strippoli
Lancet (London, England)|July 19, 2018
Metformin as first-line treatment for type 2 diabetesSuetonia C Palmer, Giovanni F M Strippoli
The Medical Journal of Australia|October 19, 2004
Combined treatment with angiotensin-converting enzyme inhibitors and angiotensin-receptor blockers to prevent end-stage kidney disease in patients who do not have diabetesGiovanni F M Strippoli, Craig C Jonathan
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|October 29, 2005
Hypothesis versus association: the optimal hemoglobin target debateGiovanni F M Strippoli, Jonathan C Craig
Nature Reviews. Nephrology|October 9, 2013
Proteinuria: does vitamin D treatment improve outcomes in CKD?Suetonia C Palmer, Giovanni F M Strippoli
Journal of Nephrology|July 12, 2013
Calcimimetics and other simple pharmacological interventions do not work in dialysis: what can we do about it?Suetonia C Palmer, Giovanni F M Strippoli
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|June 26, 2020
Long- or short-acting erythropoiesis-stimulating agents: take no shortcuts in their evaluationElisabeth M Hodson, Giovanni F M Strippoli
Pageof 22

Showing results (1-10 of 218) with videos related to

Sort By:
Pageof 22
Trials|June 11, 2010
Effects of the dose of erythropoiesis stimulating agents on cardiovascular events, quality of life, and health-related costs in hemodialysis patients: the clinical evaluation of the dose of erythropoietins (C.E. DOSE) trial protocolGiovanni F M Strippoli,
Ethnicity & Disease|June 2, 2009
Risk factors for the development and progression of renal diseases in disadvantaged populations: role of the renin-angiotensin system blockadeAusilia Maione, Giovanni F M Strippoli
Journal of Nephrology|November 8, 2011
Should we shift toward higher blood pressure targets in patients with chronic kidney disease?Giorgio Gentile, Giovanni F M Strippoli
Pediatric Nephrology (Berlin, Germany)|February 25, 2026
Artificial intelligence in pediatric nephrology: current applications and emerging frameworks for evidence generationGiovanni Pellegrino, Giovanni F M Strippoli
Lancet (London, England)|July 19, 2018
Metformin as first-line treatment for type 2 diabetesSuetonia C Palmer, Giovanni F M Strippoli
The Medical Journal of Australia|October 19, 2004
Combined treatment with angiotensin-converting enzyme inhibitors and angiotensin-receptor blockers to prevent end-stage kidney disease in patients who do not have diabetesGiovanni F M Strippoli, Craig C Jonathan
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|October 29, 2005
Hypothesis versus association: the optimal hemoglobin target debateGiovanni F M Strippoli, Jonathan C Craig
Nature Reviews. Nephrology|October 9, 2013
Proteinuria: does vitamin D treatment improve outcomes in CKD?Suetonia C Palmer, Giovanni F M Strippoli
Journal of Nephrology|July 12, 2013
Calcimimetics and other simple pharmacological interventions do not work in dialysis: what can we do about it?Suetonia C Palmer, Giovanni F M Strippoli
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|June 26, 2020
Long- or short-acting erythropoiesis-stimulating agents: take no shortcuts in their evaluationElisabeth M Hodson, Giovanni F M Strippoli
Pageof 22